Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Warner Chilcott $8.5 billion acquisition by Actavis
Davis Polk is advising Warner Chilcott plc in connection with its approximately $8.5 billion acquisition by Actavis, Inc. in…
HHS-OIG Drops Potential Action Against Howard Solomon
On August 5, 2011, the Office of Inspector General for the Department of Health and Human Services dropped a potential…
Successful patent litigation jury verdict for VNUS Medical
Davis Polk represented VNUS Medical in patent infringement litigation since 2005 in the Northern District of California…
Shareholder Plaintiff's Fee Petition in Roche-Ventana Merger Denied
On January 20, 2009, the Delaware Court of Chancery heard oral argument and denied a Ventana Medical Systems, Inc…